Nutrition and Cancer

Erscheinungsjahr 2022
ISBN: 978-0-323-90388-2
Verlag: William Andrew Publishing

Buch, Englisch, 277 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Nutrition and Cancer, Volume 373 presents a collection of chapters that describe the effect of different metabolic situations, their contribution to metabolic modulation, and their impact on tumor growth. Specific chapters in this release include Impact of obesity on cancer progression and treatment, Impact of dietary protein on cancer progression and treatment, Fasting mimicking diet and cancer therapy, Fasting and cancer responses to chemotherapy, Dietary polyamines and cancer, Ketogenic diets and cancer therapy, and Nutritional and metabolic approaches to target OXPHOS and glycolysis in cancer cells.

Zielgruppe

Academic, government and industrial sectors

Autoren/Hrsg.

Weitere Mitwirkende

Martinez, Aitziber Buque

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie

Inhaltsverzeichnis

Emergent impact of lifestyle on tumor progression and response to therapyAitziber Buqué Martinez and Lorenzo Galluzzi1. Modifying dietary amino acids in cancer patientsJosephine Connolly-Schoonen, Steven F. Biamonte, Lorraine Danowski and David C. Montrose2. Targeting amino acid metabolism in cancerLucie Safrhansova, Katerina Hlozkova and Julia Starkova3. Fasting mimicking diet in cancer therapyMaira Di Tano and Valter D. Longo4. Fasting and cancer responses to therapyJosé Manuel Bravo-San Pedro and Federico Pietrocola5. Autophagy-inducing nutritional interventions in experimental and clinical oncologySebastian J. Hofer, Guido Kroemer and Oliver Kepp6. Combination strategies to target metabolic flexibility in cancerJelena Krstic, Katharina Schindlmaier and Andreas Prokesch

Über Autor(innen)

Martinez, Aitziber Buque
Aitziber Buqué is currently a Post-Doctoral Associate with the Galluzzi Lab, in the Department of Radiation Oncology at Weill Cornell Medical College (New York), where she investigates innate and acquired mechanisms of resistance to immunotherapy in HR+ breast cancer and radiotherapy as a means to overcome them. Prior to joining the Galluzzi Lab (2018), Aitziber was a Post-Doctoral Associate with the Kroemer Lab in the Cordeliers Research Center (Paris, France; 2014-2018), after receiving her M.Sc. in Bioinformatics and Computational Biology (2006) from the Complutense University (Madrid, Spain) and her Ph.D. in Biomedicine (2013) from the BioCruces Research Institute (Barakaldo, Spain). Aitziber has a long-standing interest in the immunological mechanisms controlling cancer progression and response to treatment.